<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03782402</url>
  </required_header>
  <id_info>
    <org_study_id>7635</org_study_id>
    <nct_id>NCT03782402</nct_id>
  </id_info>
  <brief_title>Cannabinoids for Taxane Induced Peripheral Neuropathy</brief_title>
  <official_title>The Effect of Dispensed Cannabis on Taxane Induced Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Taxane-induced peripheral neuropathy (TIPN) affects a significant number of women undergoing
      breast cancer treatment. Some patients may need to shorten their course of treatment, and do
      not receive the full benefit of chemotherapy as a result. Rodent studies have shown that the
      cannabinoids may significantly improve hyperalgesia and allodynia induced by paclitaxel. The
      goal of this study is to investigate the cannabinoids THC and CBD for TIPN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators' goal is to study the efficacy of cannabinoids as a potential treatment for
      TIPN. Volunteers with a diagnosis of breast cancer and chemotherapy-induced peripheral
      neuropathy, secondary to treatment with paclitaxel or docetaxel, will be enrolled. This study
      involves the administration of cannabinoids in different strength capsules. The primary
      outcome measures include measures of pain and functional impairment (non-painful symptoms).
      The scales will include: 1) Brief Pain Inventory-Short Form (BPI) for pain severity ; and 2)
      BPI pain interference subscale for functional impairment. The study outcomes will also
      include secondary measures of perception, which will be performed in the laboratory.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brief Pain Inventory-Short Form (BPI)</measure>
    <time_frame>change over 8 weeks</time_frame>
    <description>questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy Taxane</measure>
    <time_frame>change over 8 weeks</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Neuropathy Score (TNSc) a scale of sensory, motor and autonomic symptoms</measure>
    <time_frame>change over 8 weeks</time_frame>
    <description>assessment of neuropathy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chemotherapy-induced Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Cannabinoids of varied strength</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Strengths of cannabinoids will vary across groups</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cannabinoids of various strengths</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Strengths of cannabinoids will vary across groups</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabinoids</intervention_name>
    <description>Cannabinoids with different concentrations of THC and CBD</description>
    <arm_group_label>Cannabinoids of varied strength</arm_group_label>
    <arm_group_label>Cannabinoids of various strengths</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Participants with breast cancer, experiencing TIPN due to paclitaxel or docetaxel.

          -  2) Participants must have an ECOG score of 2 or better. Participants must have a score
             of 2 or 3 score for sensory neuropathy, as assessed by the Common Toxicity Criteria
             Adverse Events (CTCAE).

          -  3) Able to give informed consent and comply with all study procedures.

        Exclusion Criteria:

          -  1) Diagnosis of a major medical, neurological, or psychiatric disorder that would
             preclude study participation.

          -  2) Women who are not practicing an effective form of birth control (condoms,
             diaphragm, birth control pill, IUD) or currently pregnant.

          -  3) Subjects taking warfarin.

          -  4) Subjects with orthostatic hypotension, hypertension, cardiovascular disease, or
             neurodegenerative disorders.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Diana Martinez, MD</last_name>
    <phone>646-774-7774</phone>
    <email>dm437@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margaret Haney, PhD</last_name>
    <phone>646-774-6574</phone>
    <email>mh235@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>1051 Riverside Drive</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Martinez, MD</last_name>
      <phone>646-774-7774</phone>
      <email>dm437@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Diana Martinez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>December 18, 2018</study_first_submitted>
  <study_first_submitted_qc>December 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2018</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Diana Martinez</investigator_full_name>
    <investigator_title>Psychiatrist II</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

